文献速递胸部肿瘤

阿米万他单抗联合拉泽替尼用于奥希替尼和铂类化疗进展后的EGFR突变非小细胞肺癌患者:CHRYSALIS-2研究A队列结果

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
PubMed 文献 · J Thorac Oncol · 2025-01-02

CHRYSALIS-2研究A队列评估阿米万他单抗联合拉泽替尼治疗奥希替尼和铂类化疗进展后的EGFR外显子19缺失或L858R突变非小细胞肺癌患者,主要终点为研究者评估的客观缓解率。结果显示研究者评估的客观缓解率为28%,盲法独立中心评估的客观缓解率为35%,中位缓解持续时间为8.3个月,中位无进展生存期为4.5个月,中位总生存期为14.8个月。

要点

  • 研究者评估的客观缓解率为28%,盲法独立中心评估的客观缓解率为35%。
  • 中位缓解持续时间为8.3个月,临床获益率为58%。
  • 中位无进展生存期为4.5个月,中位总生存期为14.8个月。

核心结论

  • 对于治疗选择有限的患者,阿米万他单抗联合拉泽替尼显示出抗肿瘤活性,安全性特征以EGFR或MET相关不良事件为特点,这些不良事件总体可控。

研究设计与样本

  • CHRYSALIS-2研究A队列评估阿米万他单抗联合拉泽替尼在EGFR外显子19缺失或L858R突变非小细胞肺癌患者中的疗效,这些患者在奥希替尼和铂类化疗期间或之后出现疾病进展。
  • 主要终点为研究者评估的客观缓解率。
  • 患者接受阿米万他单抗1050 mg静脉给药(体重≥80 kg者1400 mg)联合拉泽替尼240 mg口服。
  • A队列共纳入162例患者。

主要发现

  • 研究者评估的客观缓解率为28%(95%CI:22-36)。
  • 盲法独立中心评估的客观缓解率为35%(95%CI:27-42),中位缓解持续时间为8.3个月(95%CI:6.7-10.9),临床获益率为58%(95%CI:50-66)。
  • 中位随访12个月时,56例缓解者中32例(57%)的缓解持续时间达到或超过6个月。
  • 盲法独立中心评估的中位无进展生存期为4.5个月(95%CI:4.1-5.8),中位总生存期为14.8个月(95%CI:12.2-18.0)。
  • 在7例基线有脑病灶且既往未接受脑放疗或手术的患者中报告了中枢神经系统抗肿瘤活性的初步证据。

关键数值与推荐

  • 最常见的不良事件为皮疹(分组术语;81%)、输注相关反应(68%)和甲沟炎(52%)。
  • 最常见的≥3级治疗相关不良事件为皮疹(分组术语;10%)、输注相关反应(9%)和低白蛋白血症(6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. METHODS: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy. Primary end point was investigator-assessed objective response rate (ORR). The patients received 1050 mg of intravenous amivantamab (1400 mg if ≥ 80 kg) plus 240 mg of oral lazertinib. RESULTS: In cohort A (N = 162), the investigator-assessed ORR was 28% (95% confidence interval [CI]: 22-36). The blinded independent central review-assessed ORR was 35% (95% CI: 27-42), with a median duration of response of 8.3 months (95% CI: 6.7-10.9) and a clinical benefit rate of 58% (95% CI: 50-66). At a median follow-up of 12 months, 32 of 56 responders (57%) achieved a duration of response of more than or equal to 6 months. Median progression-free survival by blinded independent central review was 4.5 months (95% CI: 4.1-5.8); median overall survival was 14.8 months (95% CI: 12.2-18.0). Preliminary evidence of central nervous system antitumor activity was reported in seven patients with baseline brain lesions and no previous brain radiation or surgery. Exploratory biomarker analyses using next-generation sequencing of circulating tumor DNA revealed responses in patients with and without EGFR- or MET-dependent resistance. The most frequent adverse events were rash (grouped term; 81%), infusion-related reaction (68%), and paronychia (52%). The most common grade greater than or equal to 3 treatment-related adverse events were rash (grouped term; 10%), infusion-related reaction (9%), and hypoalbuminemia (6%). CONCLUSIONS: For patients with limited treatment options, amivantamab plus lazertinib demonstrated an antitumor activity with a safety profile characterized by EGFR- or MET-related adverse events, which were generally manageable.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Besse B, Goto K, Wang Y, et al. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A. J Thorac Oncol. 2025. PMID: 39755170. doi:10.1016/j.jtho.2024.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。